Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung

Apr 06 2018

• By Sue Sutter

Pages of a calendar

Related Content

Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs

Apr 04 2018

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

Apr 05 2018

Biosimilar Labeling Carve-Out Turned Erelzi's Psoriatic Arthritis, Plaque Psoriasis Uses Into 'Another Indication'

Mar 14 2018

FDA Warning Letter Calls Attention to Celltrion's 'Poor' Aseptic Practices

Feb 08 2018

Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says

Feb 07 2018

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Feb 09 2018

Humira Biosimilar Settlement Could Be Model For Other Disputes

Sep 29 2017

Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen

Aug 28 2017

Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions

Jan 24 2017

Related Companies

AbbVie Inc.

Samsung Bioepis Co., Ltd.

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Biogen, Inc.

Boehringer Ingelheim GmbH

Genentech, Inc.

Express Scripts Holding Company

Additional Topics

United States Biosimilars Legal Issues Intellectual Property Regulation BioPharmaceutical Dermatology Gastrointestinal Immune Disorders

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window